Clinical Trial

Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-13; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-08-15
Trial Details
NCT Number NCT06982963
Lead Sponsor Forte Biosciences, Inc.
Conditions Celiac Disease
Enrollment 100 participants
Start Date 2025-08-04
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-11-18